Back to Journals » ClinicoEconomics and Outcomes Research » Volume 13

Corrigendum

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]

       
Total article views   HTML views PDF downloads Totals
2,181 Dovepress* 2,110+ 311 2,421
PubMed Central* 71 37 108
Totals 2,181 348 2,529
*Since 14 July 2021

View citations on PubMed Central and Google Scholar